Targeting medullary thyroid carcinomas with bispecific antibodies and bivalent haptens. Results and clinical perspectives

Hormone Research
E RouvierJ Barbet

Abstract

The present article reviews the clinical trials that have been performed in recurrent medullary thyroid carcinoma patients with the Affinity Enhancement System. This technique uses bispecific antibodies to target radiolabelled bivalent haptens to tumour cells. Its sensitivity in the detection of known tumour sites is high (90%) and this technique also achieves good sensitivity (61%) in the detection of occult disease as revealed by abnormal thyrocalcitonin blood levels. Due to its high targeting capacity, this technique is now considered for use as a therapeutic agent in medullary thyroid carcinoma patients.

Citations

Oct 3, 2003·Journal of Molecular Recognition : JMR·Claude F MearesPaul A Whetstone
Apr 18, 2003·Cancer Immunology, Immunotherapy : CII·David M Goldenberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.